STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses ...

Mizuho has downgraded STAAR Surgical (NASDAQ:STAA ... The investment bank said the "sharpness of the correction" of China ICL sales in Q4 and "very modest" outlook for the first half of 2025 ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $19.6, a high estimate of $28.00, and a low estimate of $16.00. Observing a downward trend, the current ...

STAAR Surgical (NASDAQ:STAA – Get Free Report)‘s stock had its “equal weight” rating reiterated by research analysts at ...

Shares of Staar Surgical Co. dropped 25% on Feb. 11 after it surprised Wall Street when it reported fourth quarter sales falling 36% to $49 million.Two weeks later, the Lake Forest-based maker of ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision ...

Staar Surgical (Nasdaq:STAA) announced that it made a series of changes to realign its leadership structure to better address market needs.

Staar Surgical (NASDAQ:STAA ... The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are ...

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the following ...

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the following ...